ASR Vermogensbeheer’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$12.7M Sell
25,471
-1,220
-5% -$541K 0.13% 158
2026
Q1
$11.9M Buy
26,691
+632
+2% +$295K 0.14% 148
2025
Q4
$11.8M Sell
26,059
-235
-0.9% -$101K 0.14% 143
2025
Q3
$10.3M Sell
26,294
-125
-0.5% -$52.2K 0.12% 149
2025
Q2
$11.8M Sell
26,419
-103
-0.4% -$47.5K 0.15% 125
2025
Q1
$12.9M Buy
+26,522
New +$12.4M 0.19% 112

Other funds holding VRTX

ASR Vermogensbeheer's VRTX Position: Q2 2026 in Review

ASR Vermogensbeheer reduced its Vertex Pharmaceuticals (VRTX) stake by 4.6% in Q2 2026, selling an estimated $541K and leaving 25,471 shares worth $12.7M. The position accounts for 0.13% of the portfolio, ranked #158.

ASR Vermogensbeheer first reported a position in VRTX in Q1 2025 and has held it in 6 quarters since. The position peaked at $12.9M in Q1 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • ASR Vermogensbeheer held 25,471 shares of Vertex Pharmaceuticals worth $12.7M as of Q2 2026.
  • ASR Vermogensbeheer sold 1,220 Vertex Pharmaceuticals shares in Q2 2026, an estimated $541K.
  • Vertex Pharmaceuticals made up 0.13% of ASR Vermogensbeheer's portfolio in Q2 2026, its #158 holding.
  • ASR Vermogensbeheer first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • ASR Vermogensbeheer's Vertex Pharmaceuticals position peaked at $12.9M in Q1 2025.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on ASR Vermogensbeheer's 13F filing for Q2 2026, filed 20 Jul 2026.